Boston Scientific Corp annual revenue for fiscal TTM was $20.6 billion, an increase of 2.7% from $20.1 billion in fiscal 2025. All figures are reported results from public filings — no estimates or projections.
| Revenue (annual) | TTM → 2026-03-31 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $20.6B | $20.1B | $16.7B | $14.2B | $12.7B | $11.9B | $9.9B | $10.7B | $9.8B | $9.0B | $8.4B | $7.5B | $7.4B | $7.1B | $7.2B | $7.6B | $7.8B | $8.2B | $8.1B | $8.4B | $7.8B |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Revenue (quarterly) | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $5.2B | $5.3B | $5.1B | $5.1B | $4.7B | $4.6B | $4.2B | $4.1B |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
More BSX metrics: Gross Profit · Operating Income · Net Income · EPS · EBITDA · Free Cash Flow · Shares Outstanding
All BSX financial statements → Interactive BSX charts →
About TickerBase · Data methodology & sources